GreenLight Biosciences Holdings
GreenLight Biosciences Holdings (GRNA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
grna · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
GreenLight Biosciences HoldingsYou GRNA | $45M | N/A | — | — |
 AlloVir, Inc. ALVR | $49M | N/A | — | -$0.28 |
 bluebird bio, Inc. BLUE | $49M | N/A | — | -$24.84 |
 ERYTECH Pharma S.A. ERYP | $47M | N/A | — | -$0.01 |
 LianBio LIANY | $12M | 2.11x | — | $0.05 |
 Magenta Therapeutics, Inc. MGTA | $42M | N/A | — | $0.00 |
 Pluristem Therapeutics Inc. PSTI | $41M | N/A | — | -$0.37 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for GreenLight Biosciences Holdings (GRNA) measures how much investors pay for each dollar of the company's trailing earnings. GRNA's current PE ratio of N/A is calculated by dividing its stock price of $0.30 by its TTM earnings per share of —.
Frequently asked questions
GRNA pe ratio · 6 questionsGRNA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.30 and TTM EPS of —. Data sourced from Financial Modeling Prep via GRNA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GreenLight Biosciences Holdings SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09